Clinical Trials Browser

Urinary Bladder Neoplasms

Turcot syndrome, Colorectal Neoplasms

Nasopharyngeal Carcinoma

Advanced Breast Cancer

Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer Metastatic

Advanced Lung Cancer

Stomach Neoplasms

Nasopharyngeal Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Meningeal Carcinomatosis

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Carcinoma, Renal Cell

Advanced Malignant Solid Tumors

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Colorectal Neoplasms

Nasopharyngeal Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Nasopharyngeal Carcinoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Advanced Breast Cancer

Carcinoma, Hepatocellular, Liver Neoplasms

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Advanced Solid Tumors

Nasopharyngeal Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Carcinoma, Renal Cell

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Skin Neoplasms

Nasopharyngeal Carcinoma

Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Neoplasms

Carcinoma, Renal Cell

Muscle Invasive Bladder Cancer (MIBC)

Pancreatic Neoplasms

Clinical Trials

HOPE-07-MIBC

PICC-3

LIGHT

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NeoTOP

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

neoR-TORCH

IPROC

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

TRIPLE-PATH

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

(NeoScorch HN)

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

EC-CRT-008

FACT-TN

2025-370

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

WOLF

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

TRANSPARENT

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

TORCH-iTNT

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Study of CHS-114 in Participants With Advanced Solid Tumors

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer